Current SATVI news
The 2017 SATVI Annual Report is now available.
Researchers at the South African Tuberculosis Vaccine Initiative have co-authored an article titled "Four-gene Pan-African Blood Signature Predicts Progression to Tuberculosis" appearing in the American Journal of Respiratory and Critical Care Medicine.
The South African Tuberculosis Vaccine Initiative invites applications for a Postdoctoral Fellowship to conduct research on the Immunology of TB vaccines. Closing date 15 May 2018.
SATVI researchers have published an article titled: "Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial" appearing in the latest Lancet Respiratory Medicine.
On the eve of World TB Day we launched the "TB under the Spotlight Science Engagement" initiative in Worcester in partnership with the Division of Molecular Biology and Human Genetics at the University Stellenbosch and the Department of Education on Tuesday 20 March 2018.
Read the latest news about the fight against TB in the Cape Winelands.
Read about news in the fight against TB. Lees nuus oor die stryd teen TB.
SATVI will be launching the "Tb Under the Spotlight Science Engagement" in partnership with the Department of Education, the SA MRC Centre for Tuberculosis Research, the DST/NRF Centre of Excellence for Biomedical Tuberculosis Research, Division of Molecular Biology and Human Genetics, Stellenbosch University and UCT Anthropology on Tuesday 20 March 2018 in Worcester, Stellenbosch, and Robertson.
We have a vacancy for a Research Pharmacist at our Worcester Field site. NOW CLOSED
On Friday 17 November 75 ministers announced a landmark agreement to take urgent action to end tuberculosis (TB) by 2030 at the conclusion of a World Health Organization (WHO) conference in Moscow, Russia, on eradicating the world's deadliest infectious disease.
SATVI researchers have uncovered a sequence of biological processes that occur in humans infected with the bacterium Mycobacterium tuberculosis as the infection progresses to pulmonary tuberculosis, according to new research published in the PLOS Pathogens Journal
Associate Professor Tom Scriba has collaborated with the authors of a research paper titled: "TBVAC2020: Advancing Tuberculosis Vaccines from Discovery to Clinical Development" appearing in the Frontiers in Immunology Journal.